2026-10-30 11:00:09 UTC#545033newforecastnews
TEM stock news
TEM stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-28 08:55:52 UTC#527121duplicateconfirmednews
Temenos CEO: European sovereign AI and cloud solutions lack maturity for major bank adoption
2026-10-28 08:49:42 UTC#527072newconfirmednews
Temenos CEO says European sovereign AI and cloud solutions not yet mature for major bank adoption
2026-10-27 18:59:13 UTC#523502updateconfirmednews
Temenos AG Q3 ARR up 12%, EBIT up 26%; raises FY26 EBIT and EPS growth guidance to 12% and 10% despite deal delay
2026-10-27 17:27:05 UTC#523120newconfirmednews
Temenos AG Q3 2026 earnings call begins
2026-10-27 17:26:24 UTC#523150duplicateconfirmednews
Temenos raises full-year profit outlook citing continued momentum
2026-10-27 17:23:02 UTC#523083duplicateconfirmednews
Temenos raises 2026 EBIT growth guidance to 12% on strong Q3 ARR of $904M
2026-10-27 16:51:44 UTC#522926newconfirmednews
Temenos AG Q3 2026 ARR up 12% YoY; raises FY 2026 non-IFRS EBIT growth guidance to 12%
2026-10-27 09:46:00 UTC#519877newreportednews
Bleichmar Fonti & Auld LLP launches investigation into Personalis-Tempus AI $16.25 per share merger
tradingviewimportance 0.40trust 0.50Bleichmar Fonti & Auld LLP -0.30Personalis, Inc. -0.30Tempus AI, Inc. -0.20
2026-10-26 16:16:36 UTC#515969newconfirmedpress release
Vancity selects Temenos SaaS to modernize core banking platform
2026-10-26 12:30:00 UTC#514640newconfirmednews
Tempus AI (TEM) xR RNA sequencing assay receives EU IVDR Class C certification for solid tumor profiling
2026-10-26 11:27:00 UTC#514265newconfirmednews
HC Wainwright & Co. raises Tempus AI price target to $68.00 from $66.00, maintains Buy rating
2026-10-23 18:11:00 UTC#508382newconfirmednews
Needham maintains $75.00 price target on Tempus AI
2026-10-23 13:13:41 UTC#506840newconfirmednews
Tempus AI expands collaboration with Bristol Myers Squibb, licensing oncology data and Lens platform through 2031
2026-10-23 13:01:43 UTC#506804newconfirmednews
Pathos AI partners with Bristol Myers and Tempus AI to accelerate drug development
reutersimportance 0.50trust 0.90Pathos AI +0.40Bristol Myers Squibb Company +0.40Tempus AI, Inc. +0.40
2026-10-19 12:30:00 UTC#480427newconfirmednews
Tempus AI reports >80% sensitivity for NSCLC H&E pre-screening tool in 60,459-case ESMO 2026 study
tradingviewimportance 0.40trust 0.70Tempus AI, Inc. +0.40European Society for Medical Oncology 0Pfizer Inc. +0.30+1 entities
2026-10-15 13:08:57 UTC#465990newconfirmedpress release
Sound Credit Union selects Temenos SaaS to modernize collections operations
2026-10-14 20:39:00 UTC#461697newconfirmednews
JP Morgan maintains Neutral on Tempus AI, raises price target to $70 from $45
2026-10-09 07:00:00 UTC#436843newconfirmednews
Tempus AI Reports Q2 Revenue of $382.5M, Delivers Oncology Foundational Model to AstraZeneca
2026-10-07 13:10:00 UTC#425835duplicateconfirmednews
Tempus AI expands multiyear collaboration with Moderna and Merck for intismeran autogene commercialization
dow_jonesimportance 0.30trust 0.80Tempus AI, Inc. +0.30Moderna, Inc. +0.30Merck & Co., Inc. +0.30+2 entities